MacroGenics, Inc.
NASDAQ:MGNX
Overview | Financials
Company Name | MacroGenics, Inc. |
Symbol | MGNX |
Currency | USD |
Price | 4.46 |
Market Cap | 279,741,012 |
Dividend Yield | 0% |
52-week-range | 2.951 - 21.88 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Scott Koenig M.D., Ph.D. |
Website | https://www.macrogenics.com |
An error occurred while fetching data.
About MacroGenics, Inc.
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD